POLYMYXIN B

Polymyxin B is an antibiotic used in the treatment of gram-negative infections.

Polymyxin B treats severe bacterial infections, especially those caused by Gram-negative bacteria and multi-drug resistant strains. It is commonly used for infections like urinary tract infections, pneumonia, and ventilator-associated pneumonia caused by multidrug-resistant bacteria. This medication is available in intravenous and topical formulations, making it effective for systemic and localized bacterial infections.

Polymyxin B should be taken exactly as prescribed by a healthcare professional. It is available in various forms, such as tablets or capsules. The dosage and frequency depend on the medical condition being treated. This medication can be taken with or without food, and patients should not adjust the dosage or stop taking it without medical guidance. Following the doctor's instructions is very important, and if you experience any possible side effects, inform your healthcare provider immediately.

Polymyxin B may cause various side effects, ranging from common to rare and potentially severe. Common side effects include pain, redness, or swelling at the injection site for intravenous administration, nausea, vomiting, diarrhea, loss of appetite, and skin irritation for topical application. More serious side effects are less common but require immediate medical attention if experienced. These include allergic reactions, indicated by difficulty breathing, severe skin rash, swelling of the face, lips, or tongue, and hives. This medicine can also cause kidney damage, with symptoms such as changes in urine output, swelling in the legs or feet, and fatigue. Neurotoxicity is another serious side effect, presenting as confusion, dizziness, difficulty walking, or muscle weakness.

Polymyxin B can cause kidney and neurological problems, especially when used at higher doses or for prolonged periods. Severe allergic reactions, including anaphylaxis, can occur with this medication. It may cause gastrointestinal disturbances, including nausea, vomiting, and diarrhea. Discontinuation of this medication may lead to incomplete treatment and potential recurrence of the infection. Overuse or misuse of this medication can lead to bacterial resistance.

Regular monitoring of kidney function and neurological status is essential during treatment. If any signs of allergic reactions such as difficulty breathing, swelling, or severe skin rash develop, seek immediate medical attention. Do not stop this medication abruptly without consulting your healthcare provider. Use Polymyxin B judiciously as directed by your healthcare provider to prevent the development of antibiotic-resistant bacteria.

When using Polymyxin B, it is important to follow appropriate precautions to ensure safe and effective treatment. Inform your healthcare provider about any known allergies, particularly to antibiotics such as colistin. If you have kidney or liver problems, your doctor may need to adjust the dose and monitor you more closely.

Be alert for possible side effects, including nerve-related symptoms, skin irritation, or allergic reactions, and promptly report any new or worsening symptoms to your healthcare provider. Avoid consuming alcohol during treatment, as it may increase the risk or severity of certain side effects.

Take Polymyxin B exactly as prescribed and complete the full course of treatment, even if you begin to feel better. This can help reduce the risk of bacterial resistance and secondary infections. Follow your healthcare provider’s recommendations regarding dosing and monitoring, and inform all healthcare professionals involved in your care about the medications you are taking to help prevent potential drug interactions.

Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Protein synthesis inhibitors, and miscellaneous antibacterial agents, 12th edition, 2011, 1538 -1539. KD Tripathi, Essentials of Medical Pharmacology, Macrolide and other antibacterial antibiotics, 7th edition, 2013, 759. Bedford Laboratories, US Food, and Drug Administration, [Revised on June 2011] [ Accessed on 01st August 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/060716Orig1s020Lbl.pdf